Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Rating of “Buy” from Analysts
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) have been assigned a consensus rating of “Buy” from the five analysts that are covering the firm, Marketbeat reports. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target […]
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) have been assigned a consensus rating of “Buy” from the five analysts that are covering the firm, Marketbeat reports. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target […]
